Susan Gail Kreissman, MD
The emphasis of Dr Kreissman's clinical research involves the study of childhood neuroblastoma. Neuroblastoma is the most common extracranial solid tumor of childhood and this disease has a diverse clinical phenotype and prognosis. Dr Kreissman has developed, written, and served as national protocol chairman for 2 clinical trials designed to improve outcome for children with the high risk form of this disease through the Children's Oncology Group (COG). Results of this protocol have been published " A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma" and established the new standard of using unpurged PBSC to support autologous transplant in high risk neuroblastoma. Dr. Kreissman also serves as a member of the Neuroblastoma committees for COG and is PI for COG studies at Duke. She is involved in designing and implimenting additional new protocols for the treatment of neuroblastoma.
Education and Training
- Research Fellow, Pediatric Hematology/Oncology, Pediatrics, Children's Hospital, Boston, 1989 - 1991
- Clinical Fellow, Pediatric Hematology/Oncology, Pediatrics, Children's Hospital, Boston, 1988 - 1989
- Resident, Pediatrics, Children's Hospital, Boston, 1986 - 1988
- Intern, Pediatrics, Children's Hospital, Boston, 1985 - 1986
- M.D., Icahn School of Medicine at Mount Sinai, 1985
Selected Grants and Awards
- COG Work Order AAML: 1031--Millennium Pharmaceuticals, Inc.
- COG WORK ORDER: (PROJECT: EVERYCHILD (APEC14B1) PCR - COG FOUNDATION
- COG Work Order: AALL1131: Ph III Clofarabine in High Risk B ALL
- NCI Community Oncology Research Program (NCORP) Research Base Grant
- COG WORK ORDER: (PROJECT: PEDIATRIC MATCH (APEC1621SC) PCR - COG FOUNDATION
- COG WORK ORDER: BIQSFP AALL1131
- Per Case Reimbursement : NIH National Clinical Trials Network (NCTN)
- Workload Intensity NIH National Clinical Trials Network (NCTN)
- ALTE15N2 STUDY
- Pediatric Brain Tumor Consortium
- Stroma Biology Identifies Heparin as a Differentiating Agent in Neuroblastoma
- COG Work Order AALL07P1--Millennium Pharmaceuticals, Inc.